Davide Melisi: Predicting sensitivity to chemotherapeutic treatments in pancreatic cancer with AI
Davide Melisi, Associate Professor of Medical Oncology at University of Verona, shared a post on LinkedIn:
“I am honored to have written the editorial for this seminal study on the application of artificial intelligence-based approaches to predict sensitivity to chemotherapeutic treatments in pancreatic cancer. The potential impact of these findings on the future of cancer treatment is immense, and I am proud to have played a part in sharing this important work with the scientific community.
Congratulations to Nelson Dusetti and his colleagues for their outstanding research and these remarkable results.”
Authors: S. Casalino, C. Zecchetto , V. Merz , A. Quinzii , S. Pietrobono , D. Melisi
Nelson Dusetti reposted Davide Melisi‘s post on LinkedIn, adding:
“We are very grateful to Davide Melisi for the thoughtful editorial and to Annals of Oncology for featuring our work.”
Source: Davide Melisi/LinkedIn and Nelson Dusetti/LinkedIn
Nelson Dusetti is Scientific Director of the company Predicting Med (CSO) and Chair of TRANSLATE-IT CRCM. He is also research director at INSERM. He is the Head of the Department of Translational Research and Innovative Therapies at CRCM.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023